Anavex Life Sciences Corp.
AVXL
Biological Products, (No Diagnostic Substances)
Mkt Cap
$334.8MPE
-8.25Debt
-Cash
$139.4MEV
-FCF
-P/E Ratio
-8.25Debt
-Cash
$139.4MEV
-FCF
-Charts data: {"Earnings":[{"time":"2014-09-29","value":-11368353},{"time":"2015-09-29","value":-12108130},{"time":"2016-09-29","value":-14736698},{"time":"2017-09-29","value":-13460405},{"time":"2018-09-29","value":-17453409},{"time":"2019-09-29","value":-26294979},{"time":"2020-09-29","value":-26280470},{"time":"2021-09-29","value":-37908634},{"time":"2022-09-29","value":-47977919},{"time":"2023-09-29","value":-47505000}],"Sales":[],"Net Margins":[],"Assets":[{"time":"2014-09-29","value":7353502},{"time":"2015-09-29","value":15469913},{"time":"2016-09-29","value":9498681},{"time":"2017-09-29","value":27838329},{"time":"2018-09-29","value":24376136},{"time":"2019-09-29","value":25329373},{"time":"2020-09-29","value":34542197},{"time":"2021-09-29","value":161616490},{"time":"2022-09-29","value":152704603},{"time":"2023-09-29","value":154386000}],"Stockholders Equity":[{"time":"2014-09-29","value":192626},{"time":"2015-09-29","value":12809003},{"time":"2016-09-29","value":6308156},{"time":"2017-09-29","value":24253995},{"time":"2018-09-29","value":20491510},{"time":"2019-09-29","value":20289699},{"time":"2020-09-29","value":27236569},{"time":"2021-09-29","value":150818104},{"time":"2022-09-29","value":142491042},{"time":"2023-09-29","value":141852000}],"ROE":[{"time":"2014-09-29","value":-59.0177494211581},{"time":"2015-09-29","value":-0.9452827827427318},{"time":"2016-09-29","value":-2.3361340461459736},{"time":"2017-09-29","value":-0.5549768192827614},{"time":"2018-09-29","value":-0.8517385492821173},{"time":"2019-09-29","value":-1.295976790981473},{"time":"2020-09-29","value":-0.9648964963244819},{"time":"2021-09-29","value":-0.25135333885380234},{"time":"2022-09-29","value":-0.33670831742531576},{"time":"2023-09-29","value":-0.33489129515269433}],"ROA":[{"time":"2014-09-29","value":-0.4037498051948582},{"time":"2015-09-29","value":-0.7826889524200944},{"time":"2016-09-29","value":-1.5483289732542866},{"time":"2017-09-29","value":-0.4813793960118799},{"time":"2018-09-29","value":-0.7130196106552736},{"time":"2019-09-29","value":-1.0348774918352697},{"time":"2020-09-29","value":-0.7601660658701008},{"time":"2021-09-29","value":-0.23290364120641402},{"time":"2022-09-29","value":-0.31184015454989267},{"time":"2023-09-29","value":-0.3076574300778568}]}
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Sector
In the chart Earnings are multiplied by this value.
Earnings Growth -
Earnings Stability -
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 09-2015 | 09-2016 | 09-2017 | 09-2018 | 09-2019 | 09-2020 | 09-2021 | 09-2022 | 09-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | - | - | - | - | - | - | - | - | - | - |
| ROA | -78% | -150% | -48% | -71% | -100% | -76% | -23% | -31% | -31% | -28% |
| ROE | -95% | -230% | -55% | -85% | -130% | -96% | -25% | -34% | -33% | -30% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -56.01%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is +13.49%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -67.26%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is +17.64%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 09-2015 | 09-2016 | 09-2017 | 09-2018 | 09-2019 | 09-2020 | 09-2021 | 09-2022 | 09-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | - | - | - | - | - | - |
| Debt Equity | 0.01 | - | - | - | - | - | - | - | - | - |
| MIN | ||||||||||
| Graham Stability | - | - | - | - | - | - | - | - | - | - |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -.
What is the Graham’s Stability?
Graham’s Stability measure stands at -.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 09-2016 | 09-2018 | 09-2020 | 09-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Net Income | - | - | - | - | - |
| Stockholders Equity | 56% | 47% | 73% | -0.45% | -430% |
| FCF | - | - | - | - | - |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is -.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is -.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is +22.17%.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is -.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is +47.25%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -427.94%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -.